Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Refractory/Relapsed Rb Wild-type Extensive SCLC and Other High Grade Neuroendocrine Lung Cancers
NCT04010357Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2020
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), extrapulmonary small cell carcinoma (EPSCC), sponsored by Case Comprehensive Cancer Center. Started Jan 2020; status: completed.
02
Drugs
abemaciclib
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma of the lung (LCNEC)extrapulmonary small cell carcinoma (EPSCC)
Beyond the preview
Go deeper on NCT04010357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010357.